苏州聚微生物科技

Juwei Biotech is a synthetic biology company focused on the development of engineered live biotherapeutic products (LBPs) for metabolic and inflammatory diseases. Based in Suzhou, China, the company utilizes its proprietary microbial engineering platform to create living medicines that can colonize the human gut and perform specific therapeutic functions, such as degrading toxic metabolites. Their lead program, JW-101, is designed to treat hyperuricemia and gout by expressing enzymes that break down uric acid in the intestinal tract. Juwei Biotech's approach combines advanced genetic engineering with microbiome science to provide non-systemic, oral treatments for chronic conditions. The company is currently advancing several programs through pre-clinical development to address significant unmet medical needs in the metabolic space.